Previous studies have implied that targeting RTKs along with their downstream signaling pathways can enhance inhibitory effects, so we seek to further target Axl and MerTK in the setting of HNSCC [80,81,82]. The gene discussed is AXL; the disease is head and neck squamous cell carcinoma.